← All drugs
Drug · FAERS side-effect profile with label screen

Potassium Chloride side effects: what 113,160 FDA adverse event reports show

Potassium Chloride · Potassium Chloride Extended-Release · 1,197 reaction terms · 501,520 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Not stated in label

Brand names

Potassium Chloride Extended-Release

openFDA label

Who reports

113,160 reports · 73% serious · 15,936 with death outcome · 63% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Potassium chloride extended-release tablets are indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient.

FDA label, Indications and Usage

What it is

Potassium chloride is a metal chloride salt with a K(+) counterion. It has a role as a NMR chemical shift reference compound and a fertilizer.

PubChem CID 4873 (ChEBI)

Boxed warning

None in the current label

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled (related wording) 1Likely indication confounding 4Reporting / coding artifact 5Lab value / disease marker 4Not in label — unassessed 26
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,157 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Vaginal flatulence183279.4
221.9–351.9ROR 279.9 · calibrated p 3e-11 ✓
109.5 EB05 96.8 · IC025 +6.2
3/3 methods agree
Not in label — unassessedserious n=183 · ♀ 100% (drug 63%) · 100% clinicianno trial arm names this drug
Appendicolith206221.5
180.7–271.4ROR 221.9 · calibrated p 2e-10 ✓
99.5 EB05 88.6 · IC025 +6.1
3/3 methods agree
Not in label — unassessedserious n=206 · ♀ 0% (drug 63%) · 100% clinicianno trial arm names this drug
Sleep disorder therapy97202.6
151.7–270.6ROR 202.8 · calibrated p 8e-10 ✓
94.6 EB05 79.8 · IC025 +5.7
3/3 methods agree
Reporting / coding artifactserious n=97 · ♀ 0% (drug 63%) · 100% clinicianno trial arm names this drug
Analgesic therapy9279.2
62.0–101.2ROR 79.3 · calibrated p 9e-7 ✓
54.9 EB05 46.1 · IC025 +5.1
3/3 methods agree
Reporting / coding artifactserious n=92 · ♀ 0% (drug 63%) · 100% clinicianno trial arm names this drug
Drug therapy8566.9
52.1–85.7ROR 66.9 · calibrated p 3e-6 ✓
48.6 EB05 40.6 · IC025 +4.9
3/3 methods agree
Reporting / coding artifactserious n=85 · ♀ 0% (drug 63%) · 100% clinicianno trial arm names this drug
Device maintenance issue9336.4
29.2–45.5ROR 36.4 · calibrated p 1e-4 ✓
30.3 EB05 25.5 · IC025 +4.4
3/3 methods agree
Reporting / coding artifact♀ 100% (drug 63%) · 100% consumerno trial arm names this drug
Female genital tract fistula20524.9
21.5–28.8ROR 25.0 · calibrated p 7e-4 ✓
22.0 EB05 19.6 · IC025 +4.2
3/3 methods agree
Not in label — unassessedserious n=204 · ♀ 100% (drug 63%) · 100% clinicianno trial arm names this drug
Chronic kidney disease-mineral and bone disorder10920.8
17.0–25.3ROR 20.8 · calibrated p 0.002 ✓
18.7 EB05 15.9 · IC025 +3.8
3/3 methods agree
Not in label — unassessedserious n=109no trial arm names this drug
Radiculopathy25219.5
17.1–22.2ROR 19.5 · calibrated p 0.002 ✓
17.7 EB05 15.9 · IC025 +3.9
3/3 methods agree
Not in label — unassessedserious n=252 · ♀ 88% (drug 63%)no trial arm names this drug
Hyperparathyroidism secondary21917.5
15.2–20.0ROR 17.5 · calibrated p 0.004 ✓
16.0 EB05 14.3 · IC025 +3.7
3/3 methods agree
Not in label — unassessedserious n=218no trial arm names this drug
Infusion site discharge14416.9
14.3–20.1ROR 17.0 · calibrated p 0.004 ✓
15.5 EB05 13.5 · IC025 +3.6
3/3 methods agree
Not in label — unassessedserious n=79 · ♀ 100% (drug 63%) · 100% consumerno trial arm names this drug
Nephrogenic anaemia39216.9
15.2–18.7ROR 16.9 · calibrated p 0.004 ✓
15.5 EB05 14.3 · IC025 +3.8
3/3 methods agree
Not in label — unassessedserious n=392no trial arm names this drug
Hyperphosphataemia17416.5
14.1–19.2ROR 16.5 · calibrated p 0.005 ✓
15.2 EB05 13.4 · IC025 +3.6
3/3 methods agree
Not in label — unassessedserious n=173 · ♀ 0% (drug 63%) · 100% clinicianno trial arm names this drug
Cardioactive drug level increased10916.5
13.5–20.0ROR 16.5 · calibrated p 0.005 ✓
15.1 EB05 12.9 · IC025 +3.5
3/3 methods agree
Lab value / disease markerserious n=106no trial arm names this drug
Chronic sinusitis27814.8
13.1–16.7ROR 14.8 · calibrated p 0.008 ✓
13.7 EB05 12.4 · IC025 +3.5
3/3 methods agree
Not in label — unassessedserious n=274 · ♀ 100% (drug 63%)no trial arm names this drug
Left atrial dilatation9314.4
11.6–17.8ROR 14.4 · calibrated p 0.009 ✓
13.3 EB05 11.1 · IC025 +3.3
3/3 methods agree
Not in label — unassessedserious n=93 · ♀ 0% (drug 63%)no trial arm names this drug
Proctitis20114.2
12.3–16.4ROR 14.3 · calibrated p 0.009 ✓
13.2 EB05 11.7 · IC025 +3.5
3/3 methods agree
Not in label — unassessedserious n=201 · ♀ 100% (drug 63%) · 100% clinicianno trial arm names this drug
Oesophageal spasm12213.1
10.9–15.7ROR 13.1 · calibrated p 0.013 ✓
12.2 EB05 10.4 · IC025 +3.3
3/3 methods agree
Not in label — unassessedserious n=119 · ♀ 100% (drug 63%)no trial arm names this drug
Infusion site infection14812.9
10.9–15.2ROR 12.9 · calibrated p 0.013 ✓
12.0 EB05 10.4 · IC025 +3.3
3/3 methods agree
Not in label — unassessedserious n=82 · ♀ 100% (drug 63%) · 100% consumerno trial arm names this drug
Blood phosphorus increased17412.6
10.8–14.7ROR 12.6 · calibrated p 0.015 ✓
11.7 EB05 10.3 · IC025 +3.3
3/3 methods agree
Lab value / disease markerserious n=171 · ♀ 0% (drug 63%) · 100% clinicianno trial arm names this drug
Orthopnoea19812.2
10.6–14.1ROR 12.2 · calibrated p 0.016 ✓
11.4 EB05 10.1 · IC025 +3.2
3/3 methods agree
Not in label — unassessedserious n=189no trial arm names this drug
Metabolic alkalosis9611.8
9.6–14.5ROR 11.8 · calibrated p 0.019 ✓
11.0 EB05 9.2 · IC025 +3.1
3/3 methods agree
Likely indication confounding
term in indications
serious n=94 · 100% clinicianno trial arm names this drug
Infusion site haemorrhage18911.4
9.9–13.2ROR 11.4 · calibrated p 0.021 ✓
10.7 EB05 9.5 · IC025 +3.2
3/3 methods agree
Not in label — unassessedserious n=78 · 100% consumerno trial arm names this drug
Hypervolaemia27911.4
10.1–12.8ROR 11.4 · calibrated p 0.021 ✓
10.7 EB05 9.7 · IC025 +3.2
3/3 methods agree
Not in label — unassessedserious n=269no trial arm names this drug
Device infusion issue13610.8
9.1–12.9ROR 10.8 · calibrated p 0.025 ✓
10.1 EB05 8.8 · IC025 +3.0
3/3 methods agree
Reporting / coding artifact100% consumerno trial arm names this drug
Haemorrhagic anaemia24710.8
9.5–12.3ROR 10.8 · calibrated p 0.025 ✓
10.2 EB05 9.1 · IC025 +3.1
3/3 methods agree
Not in label — unassessedserious n=247no trial arm names this drug
Aortic stenosis19210.7
9.3–12.4ROR 10.8 · calibrated p 0.026 ✓
10.1 EB05 8.9 · IC025 +3.1
3/3 methods agree
Not in label — unassessedserious n=191 · ♀ 36% (drug 63%)no trial arm names this drug
Rebound acid hypersecretion16310.3
8.8–12.1ROR 10.4 · calibrated p 0.029 ✓
9.7 EB05 8.5 · IC025 +3.0
3/3 methods agree
Not in label — unassessedserious n=163no trial arm names this drug
Therapeutic agent toxicity17810.2
8.8–11.9ROR 10.3 · calibrated p 0.030 ✓
9.6 EB05 8.5 · IC025 +3.0
3/3 methods agree
Not in label — unassessedserious n=177no trial arm names this drug
Ischaemic cardiomyopathy1569.8
8.3–11.5ROR 9.8 · calibrated p 0.036 ✓
9.2 EB05 8.0 · IC025 +2.9
3/3 methods agree
Not in label — unassessedserious n=156 · ♀ 0% (drug 63%)no trial arm names this drug
Blood chloride decreased1299.6
8.1–11.5ROR 9.6 · calibrated p 0.038 ✓
9.0 EB05 7.8 · IC025 +2.9
3/3 methods agree
Likely indication confounding
term in indications; also in warnings
serious n=124 · 100% clinicianno trial arm names this drug
Essential hypertension1289.6
8.0–11.4ROR 9.6 · calibrated p 0.039 ✓
9.0 EB05 7.7 · IC025 +2.9
3/3 methods agree
Not in label — unassessedserious n=119no trial arm names this drug
Oxygen consumption increased1169.5
7.9–11.5ROR 9.5 · calibrated p 0.040 ✓
8.9 EB05 7.6 · IC025 +2.8
3/3 methods agree
Lab value / disease markerserious n=95 · ♀ 100% (drug 63%)no trial arm names this drug
Hypokalaemia (low potassium)2,2139.3
8.9–9.7ROR 9.5 · calibrated p 0.038 ✓
8.9 EB05 8.6 · IC025 +3.1
3/3 methods agree
Likely indication confounding
term in indications
age-adj. PRR 7.6 · serious PRR 7.1no trial arm names this drug
Brain natriuretic peptide increased1489.3
7.9–11.0ROR 9.3 · calibrated p 0.042 ✓
8.7 EB05 7.6 · IC025 +2.8
3/3 methods agree
Lab value / disease markerserious n=144no trial arm names this drug
Right ventricular failure3399.3
8.3–10.4ROR 9.3 · calibrated p 0.042 ✓
8.8 EB05 8.1 · IC025 +3.0
3/3 methods agree
Not in label — unassessedserious PRR 7.0no trial arm names this drug
Blood potassium decreased1,3868.9
8.4–9.4ROR 9.0 · calibrated p 0.046 ✓
8.5 EB05 8.1 · IC025 +3.0
3/3 methods agree
Likely indication confounding
term in indications; also in warnings
age-adj. PRR 6.9 · serious PRR 6.6no trial arm names this drug
Colitis microscopic2158.8
7.7–10.1ROR 8.9 · calibrated p 0.049 ✓
8.4 EB05 7.5 · IC025 +2.8
3/3 methods agree
Not in label — unassessedserious n=215 · ♀ 100% (drug 63%)no trial arm names this drug
Lymphoedema3168.8
7.9–9.9ROR 8.9 · calibrated p 0.049 ✓
8.4 EB05 7.7 · IC025 +2.9
3/3 methods agree
Not in label — unassessedserious n=283no trial arm names this drug

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

ConceptReportsPRR 95% CIReading
Heart failure4,2784.54.4–4.6signal
Gi bleeding3,6613.83.6–3.9signal
Arrhythmia / qt3,8093.73.6–3.8signal
Hyponatraemia1,5553.63.4–3.8signal
Anaemia5,2443.33.2–3.4signal
Kidney injury7,8373.23.1–3.3signal
Serious infection11,4402.82.7–2.8signal
Thrombocytopenia2,9782.52.4–2.6signal
Fall / fracture4,8902.42.3–2.5signal
Neutropenia / agranulocytosis3,1102.32.3–2.4signal
Venous thromboembolism2,7182.32.3–2.4signal
Hypoglycaemia9931.91.8–2.1raised
Myocardial infarction2,0341.91.8–1.9raised
Interstitial lung disease8701.71.6–1.8raised
Hyperglycaemia / diabetes3,1261.71.6–1.7raised
Pancreatitis6851.61.5–1.7raised

Trial evidence (ClinicalTrials.gov)

ClinicalTrials.gov returned results-bearing trials mentioning Potassium Chloride only as a background or rescue medication (NCT01206062, NCT00090259); no trial listing it as the tested intervention was cached, so no trial cross-check is shown.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Diarrhoea (diarrhea)8,2412.4
2.3–2.4ROR 2.5 · calibrated p 0.813
2.4 EB05 2.3 · IC025 +1.2
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 2.0 · serious PRR 2.3no trial arm names this drug
Dyspnoea (shortness of breath)8,1322.7
2.6–2.7ROR 2.8 · calibrated p 0.689
2.7 EB05 2.6 · IC025 +1.4
3/3 methods agree
Not in label — unassessedage-adj. PRR 2.2 · serious PRR 2.4no trial arm names this drug
Nausea7,8891.9
1.8–1.9ROR 1.9 · calibrated p 0.902
1.9 EB05 1.8 · IC025 +0.9Labeled adverse reaction
exact term
age-adj. PRR 1.7 · serious PRR 2.0no trial arm names this drug
Fatigue (tiredness)7,8811.9
1.8–1.9ROR 2.0 · calibrated p 0.919
1.9 EB05 1.8 · IC025 +0.9Not in label — unassessedage-adj. PRR 1.6 · serious PRR 1.9no trial arm names this drug
Death5,6861.2
1.2–1.3ROR 1.2 · calibrated p 0.464
1.2 EB05 1.2 · IC025 +0.2Outcome field, not a reactionage-adj. PRR 1.1 · serious PRR 1.0no trial arm names this drug
Pneumonia (lung infection)5,4513.2
3.1–3.2ROR 3.3 · calibrated p 0.545
3.1 EB05 3.1 · IC025 +1.6
3/3 methods agree
Not in label — unassessedage-adj. PRR 2.6 · serious PRR 2.5no trial arm names this drug
Headache5,0811.5
1.5–1.5ROR 1.5 · calibrated p 0.661
1.5 EB05 1.5 · IC025 +0.5Not in label — unassessedage-adj. PRR 1.4 · serious PRR 1.5no trial arm names this drug
Asthenia (weakness)5,0702.5
2.4–2.6ROR 2.6 · calibrated p 0.776
2.5 EB05 2.4 · IC025 +1.3
3/3 methods agree
Not in label — unassessedage-adj. PRR 1.9 · serious PRR 2.3no trial arm names this drug
Dizziness4,9401.8
1.8–1.9ROR 1.9 · calibrated p 0.879
1.8 EB05 1.8 · IC025 +0.8Not in label — unassessedage-adj. PRR 1.5 · serious PRR 1.9no trial arm names this drug
Vomiting4,8881.9
1.9–2.0ROR 2.0 · calibrated p 0.935
1.9 EB05 1.9 · IC025 +0.9Labeled adverse reaction
exact term
age-adj. PRR 1.9 · serious PRR 1.9no trial arm names this drug
Pain4,8531.5
1.4–1.5ROR 1.5 · calibrated p 0.632
1.5 EB05 1.4 · IC025 +0.5Labeled adverse reaction
exact term
age-adj. PRR 1.6 · serious PRR 1.4no trial arm names this drug
Off label use (used outside approved label)4,6841.0
1.0–1.0ROR 1.0 · calibrated p 0.306
1.0 EB05 1.0 · IC025 -0.0
PRR-only: not supported by EBGM or IC
Reporting / coding artifactage-adj. PRR 1.0 · serious PRR 1.1no trial arm names this drug
Fall4,5982.6
2.5–2.7ROR 2.6 · calibrated p 0.752
2.6 EB05 2.5 · IC025 +1.3
3/3 methods agree
Not in label — unassessedage-adj. PRR 1.9 · serious PRR 2.2no trial arm names this drug
Drug ineffective (drug did not work)4,4620.6
0.6–0.6ROR 0.6 · calibrated p 0.089
0.6 EB05 0.6 · IC025 -0.7
PRR-only: not supported by EBGM or IC
Reporting / coding artifactage-adj. PRR 0.8 · serious PRR 0.8no trial arm names this drug
Anaemia (low red blood cells)3,6993.6
3.5–3.8ROR 3.7 · calibrated p 0.432
3.6 EB05 3.5 · IC025 +1.8
3/3 methods agree
Not in label — unassessedage-adj. PRR 2.9 · serious PRR 3.0no trial arm names this drug

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Potassium Chloride?

In FDA FAERS, the most frequently co-reported reaction terms for Potassium Chloride are diarrhoea, dyspnoea, nausea, fatigue, pneumonia, headache. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Potassium Chloride have an FDA boxed warning?

No. The FDA label retrieved for Potassium Chloride has no boxed warning; see the label's Warnings and Precautions for the recognised risks.

Do FAERS signals prove that Potassium Chloride causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.